Blood Urea Nitrogen Diagnostics Market Outlook:
Blood Urea Nitrogen Diagnostics Market size was valued at USD 2.4 billion in 2025 and is projected to reach USD 4.7 billion by the end of 2035, rising at a CAGR of 7.9% during the forecast period 2026-2035. In 2026, the industry size of blood urea nitrogen diagnostics is estimated at USD 2.5 billion.
The global market is provided with impetus by the rising instances of chronic kidney disease in patients. As per a report by the NLM in March 2022, chronic kidney disease (CKD) is a public health problem with abnormalities in kidney structure or function that persist for at least a few months and affects over 10% of the population worldwide, or more than 800 million people. Kidney failure is reported by the CDC as being mainly caused by diabetes and hypertension. Blood urea nitrogen tests carried out through public health networks have been on the rise in the market lately due to the proliferating number of screening programs and preventative care initiatives being sponsored by the government.
The supply chain of the blood urea nitrogen diagnostics covers biochemical substrates, reagents, and disposable cartridges for analyzers. These are principally manufactured in North America, the APAC region, and Europe. As per a report by World Integrated Trade Solutions in October 2025, in 2023, India imported prepared enzymes (HS 350790) worth USD 137,709.3k (USD 137.7 million) and 19,184,800 kilograms, with purported imports from Germany to a tune of USD 7,923.2k. Some of the vital elements, such as colorimetric agents and urease enzymes, tend to be imported from India, Germany, and the U.S. The blood urea nitrogen diagnostics market is also bolstered by advancements in AI-integrated diagnostic platforms and enhancements in renal detection.
